Aims: INI1 expression and its correlation with MGMT gene promoter methylation status and follow-up was investigated in 77 surgically removed glioblastomas then treated with radiotherapy (RT) or RT plus temozolomide (TMZ).Methods: INI1 was determined by immunohistochemistry and MGMT by methylation-specific PCR.Results: INI1 was expressed in 83.1% of cases. The median overall survival (OS) was 13.6 months in INI1+ tumours and 7.2 months in INI1- tumours. 31.3% of patients with INI1+ tumours were alive compared with 15.4% of patients with INI1- tumours. MGMT methylation was detected in 31.2% of cases. OS was significantly different between patients with methylated tumours and un-methylated tumours (p < 0.04), and between patients with RT+ TMZ and RT alone (p < 0.001). Considering both treatment and MGMT, the difference in OS was significant (p < 0.002). The difference in OS according to MGMT and INI1 was significant (p < 0.04). The longest median OS was recorded among methylated and INI1+ tumours. Among un-methylated tumours, the median OS was 11.1 months in INI1+ and 6.5 months in INI1- tumours. No patients were alive with un-methylated and INI1- tumours.Conclusions: Loss of INI1 immunohistochemical expression in glioblastoma may be indicating an underlying molecular aberration accounting for the more aggressive clinical behaviour.
|Data di pubblicazione:||2011|
|Titolo:||INI1 immunohistochemical expression in glioblastoma: correlation with MGMT gene promoter methylation status and patient survival|
|Autore/i:||E. Zunarelli; N. Bigiani; G. Sartori; M. Migaldi; A. Sgambato; A. Maiorana|
|Codice identificativo ISI:||WOS:000286040500003|
|Codice identificativo Scopus:||2-s2.0-80052250087|
|Citazione:||INI1 immunohistochemical expression in glioblastoma: correlation with MGMT gene promoter methylation status and patient survival / E. Zunarelli; N. Bigiani; G. Sartori; M. Migaldi; A. Sgambato; A. Maiorana. - In: PATHOLOGY. - ISSN 0031-3025. - ELETTRONICO. - 43(2011), pp. 17-23.|
|Tipologia||Articolo su rivista|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris